Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Sotrovimab  COVID-19 treatment studies for Sotrovimab  C19 studies: Sotrovimab  Sotrovimab   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 38% Improvement Relative Risk Hospitalization 18% primary Progression -3% c19early.org/v Aggarwal et al. Sotrovimab for COVID-19 EARLY Is early treatment with sotrovimab beneficial for COVID-19? Retrospective 30,247 patients in the USA (December 2021 - March 2022) Lower hospitalization with sotrovimab (not stat. sig., p=0.32) Aggarwal et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2022.10.002 Favors sotrovimab Favors control
Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality for At-risk COVID-19 Outpatients During an Omicron BA.1 and BA.1.1-Predominant Phase
Aggarwal et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.10.002 (date from earlier preprint)
Aggarwal et al., Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality for At-risk COVID-19.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.10.002 (date from earlier preprint)
Jun 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 30,247 outpatients in the USA, showing no significant differences with sotrovimab with omicron BA.1.
Efficacy is variant dependent. In Vitro studies predict lower efficacy for BA.1 [Liu, Sheward, VanBlargan] and a lack of efficacy for BA.2 [Zhou]. US EUA has been revoked.
risk of death, 38.0% lower, RR 0.62, p = 0.62, treatment 1 of 1,542 (0.1%), control 7 of 3,663 (0.2%), odds ratio converted to relative risk.
risk of hospitalization, 17.5% lower, RR 0.82, p = 0.32, treatment 39 of 1,542 (2.5%), control 116 of 3,663 (3.2%), NNT 157, odds ratio converted to relative risk, primary outcome.
risk of progression, 2.8% higher, RR 1.03, p = 0.83, treatment 93 of 1,542 (6.0%), control 224 of 3,663 (6.1%), NNT 1189, odds ratio converted to relative risk, ED visit.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Aggarwal et al., 18 Jun 2022, retrospective, USA, peer-reviewed, 10 authors, study period 26 December, 2021 - 10 March, 2022.
Contact: neil.aggarwal@cuanschutz.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperSotrovimabAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.06.17.22276575; this version posted June 18, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 2 Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients During the Omicron Phase 3 4 Neil R. Aggarwal, MD, MHSca*; Laurel E. Beaty, MSb*; Tellen D. Bennett, MD, MS c,e; Nichole E. Carlson, PhD, MSb,e; Adit A. Ginde, MD, MPHd,e 5 a Department of Medicine, University of Colorado School of Medicine, Aurora, 80045, USA 6 7 b 8 9 c Section of Informatics and Data Science, Department of Pediatrics, University of Colorado Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, 80045, USA School of Medicine, Aurora, 80045, USA 10 11 d 12 13 e Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz 14 * Contributed equally to this manuscript 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 See Supplement for a full list of Contributors. Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, 80045, USA Medical Campus, Aurora, 80045, USA Corresponding author: Neil R. Aggarwal, MD, MHSc Department of Medicine University of Colorado School of Medicine 12700 E. 19th Ave, Mail Stop C-272 Aurora, CO 80045, USA Phone: +1-303-724-6038 Email: neil.aggarwal@cuanschutz.edu Running title: Sotrovimab for COVID-19 Outpatients Word counts: Abstract: 199, Manuscript text: 2924 Summary: Real-world evidence demonstrates that the neutralizing monoclonal antibody sotrovimab was not associated with lower 28-day hospitalization and mortality rates when administered to high-risk outpatients recently infected with SARS-CoV-2 during the Omicron variant phase, compared to a propensity-matched cohort of untreated outpatients. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2022.06.17.22276575; this version posted June 18, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 33 ABSTRACT 34 Background: Sotrovimab, a neutralizing monoclonal antibody (mAb) treatment authorized for 35 early symptomatic COVID-19 patients, was effective in preventing the progression of severe 36 disease and mortality following SARS-CoV-2 Delta variant infection. It is not known whether 37 sotrovimab is similarly effective for SARS-CoV-2 Omicron variant infection. 38 Methods: Observational cohort study of non-hospitalized adult patients with SARS-CoV-2 39 infection from December 26, 2021 to March 10, 2022 (>96% Omicron BA.1 variant), using 40 electronic health records from a statewide health system linked to state-level vaccine and 41 mortality data. We used propensity matching to select up to 3 patients not receiving mAbs or 42 other authorized antivirals for each patient who received outpatient sotrovimab treatment. The 43 primary outcome was 28-day hospitalization; secondary outcomes included mortality. To 44 evaluate change in..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit